The Hamburg-based company Indivumed has repositioned itself, sending a clear message with a recent change in leadership: A new chapter is beginning with the focus on discovering and developing novel therapeutic targets for innovative cancer therapies. |transkript spoke with Prof. Dr. Hartmut Juhl and Dr. Matthias Evers.
ADVERTISEMENT
Tag Archive for: Cancer therapeutics
Krakow-based oncology specialist Ryvu Therapeutics zoo today announced a strategic reorganisation that will extend Ryvu’s cash runway to H2/2026 to focus on accelerating three ongoing RVU120 clinical programmes, and early pipeline small molecule and ADC assets to key data inflection points.